Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has partnered with Symatese to commence distribution of Nuceiva® (botulinum toxin type A) in France.
Nuceiva® is approved by the European Commission for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age2.
“Launching Nuceiva® in France in partnership with Symatese marks a milestone in our commitment to strategic geographic expansion,” said David Moatazedi, President and Chief Executive Officer of Evolus. “We entered a key region that advances our global growth strategy and reinforces our dedication to international customers. Our successful track record of driving adoption in new markets continues to position us for growth as a global leader in the industry.”
Symatese is a privately held French company with a long-standing presence in the aesthetics industry and a direct presence in France. It designs, engineers and manufactures regenerative medical solutions based on proprietary technology platforms. Symatese has cultivated strong, longstanding relationships with French aesthetic clinicians and is well-positioned to be the exclusive distributor of Nuceiva® in France.
“We are pleased to launch Nuceiva® in France, once again highlighting the strong partnership between Evolus and Symatese. This achievement was made possible through the close collaboration between our teams in both companies,” said Jean-Paul Gérardin, Chief Executive Officer of Symatese. “It reflects our ongoing commitment to bringing innovative solutions to the French medical community.”
Nuceiva® is licensed in the United States under the brand name Jeuveau® and is the fastest-growing neurotoxin in the United States for four consecutive years*.
Dr. Patrick Trevidic, a renowned plastic, reconstructive and aesthetic surgeon based in Paris, France and Head of the Plastic and Aesthetic Surgery Department at Paris Hospital Sainte-Anne commented, “The aesthetics market in France and across Europe is undergoing a significant transformation, led by a younger generation that values subtle, non-surgical treatment options. With its distinctly millennial appeal, Evolus is expanding into the French market to introduce its innovative neuromodulator Nuceiva®, through its strategic partnership with Symatese. As a clinical investigator for Nuceiva®, I can confirm it provides aesthetic practitioners with enhanced versatility and choice—empowering us to deliver clinically proven, effective treatments.”
The safety and efficacy of Nuceiva® was evaluated through the company’s TRANSPARENCY clinical program – three Phase III trials3,4 including the largest head-to-head aesthetic pivotal study versus Botox® (botulinum toxin type A) to date, and two long-term safety studies5,6. Side effects were similar to others in this class of medicine. For the full list of adverse events, warnings and contraindications consult the Nuceiva® SmPC.
